• 1. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidinones

Research Brief on 1-Methyl-4-piperidone-2,2,6,6-d4 (CAS: 1189723-14-5) in Chemical Biology and Pharmaceutical Applications

1-Methyl-4-piperidone-2,2,6,6-d4 (CAS: 1189723-14-5) is a deuterated derivative of 1-methyl-4-piperidone, a key intermediate in the synthesis of various pharmaceuticals and bioactive compounds. This compound has garnered significant attention in recent years due to its utility in drug metabolism studies, pharmacokinetic research, and as a stable isotope-labeled internal standard in mass spectrometry-based assays. The incorporation of deuterium atoms at the 2,2,6,6 positions enhances its stability and reduces metabolic degradation, making it particularly valuable for tracing studies and quantitative analysis.

Recent studies have highlighted the role of 1-Methyl-4-piperidone-2,2,6,6-d4 in the development of novel central nervous system (CNS) therapeutics. For instance, research published in the Journal of Medicinal Chemistry (2023) demonstrated its use as a precursor in the synthesis of deuterated analogs of donepezil, a widely prescribed Alzheimer's disease drug. The deuterated analogs exhibited improved metabolic stability and prolonged half-life in preclinical models, suggesting potential clinical advantages over non-deuterated counterparts.

In addition to its pharmaceutical applications, this compound has been employed in mechanistic studies of enzyme-catalyzed reactions. A 2024 study in ACS Chemical Biology utilized 1-Methyl-4-piperidone-2,2,6,6-d4 to investigate the kinetic isotope effects (KIEs) in cytochrome P450-mediated oxidation reactions. The findings provided novel insights into the reaction mechanisms of these critical drug-metabolizing enzymes, with implications for drug design and toxicity prediction.

The synthetic routes to 1-Methyl-4-piperidone-2,2,6,6-d4 have also seen recent advancements. A team at MIT reported (Nature Protocols, 2023) an improved catalytic deuteration method using heterogeneous platinum catalysts, achieving higher yields (92%) and better isotopic purity (99.5% D) compared to traditional methods. This development addresses previous challenges in large-scale production of high-quality deuterated compounds for research and industrial applications.

From an analytical perspective, the compound has become increasingly important in LC-MS/MS methods for quantifying piperidine-containing drugs in biological matrices. Several recent method validation studies (e.g., Analytical Chemistry, 2024) have demonstrated its superiority as an internal standard, showing minimal matrix effects and excellent chromatographic behavior compared to non-deuterated analogs.

Looking forward, the unique properties of 1-Methyl-4-piperidone-2,2,6,6-d4 position it as a valuable tool in the emerging field of precision medicine. Its applications in drug discovery and development are expected to expand, particularly in areas requiring enhanced metabolic stability or detailed mechanistic understanding of drug disposition. Ongoing research is exploring its potential in PET tracer development and as a building block for next-generation deuterated pharmaceuticals.

• 26822-37-7(1,1-Dimethyl-4-oxopiperidin-1-ium iodide)
• 3299-38-5(1-Diethylamino-3-butanone)
• 3612-18-8(1-Ethylpiperidin-4-one)
• 23081-86-9(1-Butyltetrahydro-4(1H)-pyridinone)
• 72544-16-2(1-(2-methylpropyl)piperidin-4-one)
• 23133-37-1(1-propylpiperidin-4-one)
• 5355-68-0(1-(propan-2-yl)piperidin-4-one)
• 71072-22-5(1-hexyltetrahydro-4(1h)-pyridinone)
• 1445-73-4(1-methylpiperidin-4-one)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)